Health, Safety and Environment (HSE) in Brazil
The Brazilian Health Regulatory Agency (ANVISA) recently approved a Regulatory Impact Analysis (RIA) report on medical cannabis. This development marks an important step towards the potential reshaping of cannabis regulations in Brazil, promising wide-ranging implications for public health, medical research, Read More …
Brazil’s National Health Regulatory Agency (Agência Nacional de Vigilância Sanitária – Anvisa) has recently updated its list of Brazilian Common Denominations (Denominações Comuns Brasileiras – DCB), an essential step for the standardization and regulation of pharmaceutical substances in Brazil. The Read More …
ANVISA has launched Call No. 1, aimed at supporting the development of phytotherapeutic drugs, new synthetic drugs and biological products of interest to healthcare services by medical startups. Recognizing the critical need for new medications and the importance of nurturing Read More …
The Brazilian Health Regulatory Agency (Anvisa) has recently introduced new subject codes for the streamlined evaluation of medicines, biological products, vaccines, and Active Pharmaceutical Ingredient (API) Dossier Suitability Letters. These codes facilitate the use of assessments conducted by equivalent foreign regulatory authorities, enhancing regulatory confidence and Read More …
In the ever-evolving landscape of public health and safety, the Brazilian Health Regulatory Agency (Anvisa) plays a critical role in safeguarding the well-being of its citizens. The agency’s recent initiative to enhance transparency in its drug evaluation process is a Read More …
During its public Collegiate Board meeting on March 19, 2024, Anvisa approved an instructional norm aimed at establishing criteria for the use of assessments from foreign equivalent regulatory authorities within its framework. This recent Anvisa approval represents a significant milestone Read More …